Smarcc1 Antibody

What is SMARCC1 and what is its function in cellular processes?

SMARCC1 is a core subunit of the SWI/SNF family of proteins that display helicase and ATPase activities. The protein functions primarily in regulating transcription by altering chromatin structure around specific genes . As part of the large ATP-dependent chromatin remodeling complex SNF/SWI, SMARCC1 contains a predicted leucine zipper motif typical of many transcription factors . It's necessary for efficient nucleosome remodeling by BRG1 in vitro and serves as an essential component of the mouse embryonic stem cell-specific SWI/SNF complex (esBAF), which is crucial for early embryogenesis, particularly proper brain and visceral endoderm development .

Which applications can SMARCC1 antibodies be used for in research?

SMARCC1 antibodies have been validated across multiple experimental platforms:

What is the molecular weight of SMARCC1 protein?

There is a notable discrepancy between calculated and observed molecular weights for SMARCC1:

• Calculated molecular weight: 123 kDa (1105 amino acids)

• Observed molecular weight in experiments: 155-160 kDa

This difference likely reflects post-translational modifications and structural characteristics that affect protein migration in SDS-PAGE. Researchers should anticipate detecting SMARCC1 at approximately 155-160 kDa in their Western blot experiments.

What are the recommended dilutions for SMARCC1 antibodies in different applications?

Optimal dilutions vary by antibody source and application:

Proteintech antibody (17722-1-AP):

• Western Blot: 1:2000-1:16000

• Immunoprecipitation: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

• Immunohistochemistry: 1:250-1:1000

Cell Signaling antibody (#11956):

• Western Blotting: 1:1000

• Immunoprecipitation: 1:50

• Chromatin IP and ChIP-seq: 1:100

• CUT&RUN and CUT&Tag: 1:100

ABClonal antibody (A4275):

• Western Blot: 1:500-1:2000

• IF/ICC: 1:50-1:200

• ChIP: 5μg antibody for 10-15μg of chromatin

• ELISA: Starting concentration of 1 μg/mL (optimize based on specific assay requirements)

It is recommended that researchers titrate these reagents in each testing system to obtain optimal results, as outcomes can be sample-dependent .

How should antigen retrieval be performed for optimal SMARCC1 immunohistochemistry?

For optimal IHC results with SMARCC1 antibodies:

• Primary recommendation: TE buffer at pH 9.0

• Alternative approach: Citrate buffer at pH 6.0

• High-temperature method: EDTA buffer under high temperature and high pressure conditions, as used in renal cell carcinoma research

The selection of antigen retrieval method should be determined by tissue type and fixation conditions. Comparison of multiple methods may be necessary for optimization with specific tissue samples.

What is the optimal protocol for ChIP-seq experiments when studying SMARCC1?

For ChIP and ChIP-seq applications:

• Use 5 μl of antibody and 10 μg of chromatin (approximately 4 × 10^6 cells) per IP

• Validate results using established ChIP kit protocols (e.g., SimpleChIP® Enzymatic Chromatin IP Kits)

• For CUT&RUN applications, determine dilutions using CUT&RUN Assay Kit #86652

• For CUT&Tag applications, determine dilutions using CUT&Tag Assay Kit #77552

• When using ABClonal antibody, use 5μg antibody for 10-15μg of chromatin

These protocols have been validated in research settings and provide a starting point for optimization in specific experimental contexts.

What controls and validation methods should be used when working with SMARCC1 antibodies?

Comprehensive validation of SMARCC1 antibodies should include:

• Knockout (KO) validation, as mentioned with the ABClonal antibody (A4275)

• Cross-reactivity testing across species (human, mouse, rat, monkey)

• Western blot analysis using various cell lysates:

  • K-562 cells, Jurkat cells

  • Rat brain tissue, rat testis tissue

• Positive IP controls using mouse brain tissue

• Multiple tissue type validation for IHC:

  • Human malignant melanoma, appendicitis, brain, kidney, ovary, placenta, and testis tissues

Including appropriate negative controls (e.g., isotype controls, knockout/knockdown samples) is essential for confirming antibody specificity.

How does SMARCC1 expression correlate with disease progression in cancer research?

Studies on clear cell renal cell carcinoma (ccRCC) have shown significant correlations between SMARCC1 expression and disease parameters:

• SMARCC1 expression is significantly decreased in ccRCC tissues compared to corresponding para-tumor tissue (4.370±2.036 vs. 6.167±1.162, P=0.001)

• SMARCC1 expression is positively correlated with pathological grade (r=0.224, P=0.011)

• Prognostic significance: Patients with high SMARCC1 expression demonstrated better prognosis than those with low expression (40.0% vs. 95.2%, P=0.000)

• This prognostic relationship was particularly pronounced in specific subgroups:

  • Pathological grade III and IV

  • Male patients (73.5% vs. 95.3%, P=0.004)

  • Tumor size >5 cm (62.5% vs. 89.5%, P=0.044)

These findings suggest SMARCC1 may serve as a potential prognostic marker in ccRCC and potentially other cancers.

What quantification methods are recommended for SMARCC1 expression in tissue samples?

Research on SMARCC1 has employed several quantification approaches:

For immunohistochemistry scoring:

• Percentage of positively stained cells:

  • 0 (Negative)

  • 1 (0-1%)

  • 2 (21-40%)

  • 3 (41-60%)

  • 4 (61-80%)

  • 5 (81-100%)

• Staining intensity scores:

  • 0 (Negative)

  • 1 (1+)

  • 2 (2+)

  • 3 (3+)

• Total score calculation: percentage score × intensity score

• Expression classification: ≤2.5 considered low expression, >2.5 considered high expression

For qRT-PCR analysis:

• Validated primers:

  • SMARCC1-F: 5'-TGAGGAGGATTATGAGGTGG-3'

  • SMARCC1-R: 5'-CGTGATTCTGTTGGTGTCG-3'

  • Product length: 177 bp

• Reference gene: β-actin

  • Human β-actin-F1: 5'-GAAGAGCTACGAGCTGCCTGA-3'

  • Human β-actin-R1: 5'-CAGACAGCACTGTGTTGGCG-3'

Standardized quantification methods facilitate comparison across different studies and should be clearly documented in research protocols.

What are the best cell and tissue models for studying SMARCC1 function?

Based on validated antibody applications, several models have demonstrated reliable SMARCC1 detection:

Cell lines:

• K-562 cells (human chronic myelogenous leukemia)

• Jurkat cells (human T lymphocyte)

Animal tissues:

• Rat brain and testis tissue (Western blot validated)

• Mouse brain tissue (IP validated)

Human tissues with positive IHC detection:

• Malignant melanoma tissue

• Appendicitis tissue

• Brain tissue

• Kidney tissue

• Ovary tissue

• Placenta tissue

• Testis tissue

The selection of appropriate models should align with specific research questions, considering factors such as species conservation, tissue-specific expression patterns, and experimental readouts.

How can researchers resolve discrepancies in SMARCC1 detection across different experimental systems?

When facing inconsistent results:

• Consider antibody specificity and validation status for the specific application

• Evaluate the discrepancy between calculated (123 kDa) and observed (155-160 kDa) molecular weights

• Account for potential post-translational modifications affecting protein detection

• Optimize buffer conditions, especially for challenging applications:

  • For IHC: Test both TE buffer (pH 9.0) and citrate buffer (pH 6.0)

  • For IP: Ensure appropriate antibody-to-protein ratios (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate)

• Consider species-specific variations in SMARCC1 sequence and structure

What are the emerging applications for SMARCC1 antibodies in chromatin biology research?

Recent technical advances include:

• CUT&RUN and CUT&Tag assays for high-resolution chromatin mapping

• Integration with single-cell technologies for understanding cell-specific SMARCC1 functions

• Combinatorial approaches using multiple SWI/SNF complex antibodies to understand complex assembly and dynamics

How should researchers design experiments to investigate SMARCC1's role in developmental processes?

Based on current understanding of SMARCC1's role in embryonic stem cells:

• Focus on the esBAF complex (embryonic stem cell-specific SWI/SNF complex)

• Design time-course experiments to track SMARCC1 expression and localization during differentiation

• Implement conditional knockout/knockdown approaches to assess stage-specific requirements

• Combine with lineage tracing to understand tissue-specific functions, particularly in brain and visceral endoderm development

• Consider the relationship between SMARCC1 and other chromatin remodeling factors in developmental contexts